A Phase IIB Study to Assess the Efficacy of GSK 249553 [MAGE-A3 ASCI] as Adjuvant Therapy Given to MAGE-3-Positive Patients With Non-Small-Cell Lung Cancer in Stage IB (T2/N0) or II (T1/N1 or T2/N1 or T3/N0), Who Have Had Complete Surgical Resection.
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Zastumotide (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 28 May 2013 Results published in the Journal of Clinical Oncology.
- 01 Jul 2011 Primary endpoint 'Disease-free-survival-duration' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History